Paper 20 - SUSTAINED DISEASE CONTROL WITH MDM2 INHIBITOR MILADEMETAN IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

Author(s)

• 

  Mrinal M. Gounder, MD

  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center
  New York, New York, United States

  Slides PDF

Co-Author(s)

• AW

  Amy M. Weise, DO

  Barbara Ann Karmanos Cancer Institute, Karmanos Cancer Institute
  Detroit, Michigan, United States
• PK

  Prasanna Kumar, PhD

  Senior Director, Oncology R&D
  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• 

  Ben Tao, MS

  Associate Director, Biostatistics
  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• AL

  Arnaud Lesegretain, MBA

  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• VT

  Vijaya G. Tirunagaru, PhD

  Rain Therapeutics, Inc.
  Newark, California, United States
• 

  Feng Xu, MS (he/him/his)

  Head of Biometrics
  Rain Therapeutics, Inc.
  Newark, California, United States
• RB

  Richard Bryce, MBChB, MRCGP, MFPM

  Rain Therapeutics, Inc.
  Newark, California, United States
• DH

  David S. Hong, MD

  Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States